Advance in biologics for chronic rhinosinusitis with nasal polyps - PubMed
4 hours ago
- #CRSwNP
- #biologics
- #type 2 inflammation
- Chronic rhinosinusitis with nasal polyps (CRSwNP) is challenging to manage, especially when conventional treatments fail.
- CRSwNP is often associated with type 2 inflammation and comorbid conditions like asthma.
- Four biologics are approved for CRSwNP: dupilumab, omalizumab, mepolizumab, and stapokibart (approved in China).
- Biologics improve quality of life, reduce the need for systemic corticosteroids and endoscopic sinus surgery (ESS), and help manage comorbid conditions.
- Clinical trials and real-world data highlight the effectiveness and safety of biologics for CRSwNP.
- The article compares biologic therapy with ESS and explores switching or simultaneous use of biologics.